RESUMEN
An advance directive is an essential document for providing a better understanding of an end-of-life situation. It is not imposed on the doctor but must nevertheless be taken into account in the decision-making. The application of the directive invites a time of reflection on ethics and discussion among peers.
Asunto(s)
Directivas Anticipadas , Ética Clínica , Toma de Decisiones , HumanosRESUMEN
Some neurodegenerative diseases gradually affect the patient's consciousness. While the patient may be declared incompetent, decisions concerning treatment must take into account his or her wishes, however weakly they may be expressed. A real ethical challenge for all the caregivers who must ensure the person's dignity is maintained and refrain from demonstrating therapeutic obstinacy.
Asunto(s)
Coma , Competencia Mental/legislación & jurisprudencia , Estado Vegetativo Persistente , Beneficencia , Ética Médica , Humanos , Derechos del Paciente/legislación & jurisprudencia , Autonomía PersonalRESUMEN
Ataxia with ocular motor apraxia type 1 (AOA1) is an autosomal recessive cerebellar ataxia (ARCA) associated with oculomotor apraxia, hypoalbuminaemia and hypercholesterolaemia. The gene APTX, which encodes aprataxin, has been identified recently. We studied a large series of 158 families with non-Friedreich progressive ARCA. We identified 14 patients (nine families) with five different missense or truncating mutations in the aprataxin gene (W279X, A198V, D267G, W279R, IVS5+1), four of which were new. We determined the relative frequency of AOA1 which is 5%. Mutation carriers underwent detailed neurological, neuropsychological, electrophysiological, oculographic and biological examinations, as well as brain imaging. The mean age at onset was 6.8 +/- 4.8 years (range 2-18 years). Cerebellar ataxia with cerebellar atrophy on MRI and severe axonal sensorimotor neuropathy were present in all patients. In contrast, oculomotor apraxia (86%), hypoalbuminaemia (83%) and hypercholesterolaemia (75%) were variable. Choreic movements were frequent at onset (79%), but disappeared in the course of the disease in most cases. However, a remarkably severe and persistent choreic phenotype was associated with one of the mutations (A198V). Cognitive impairment was always present. Ocular saccade initiation was normal, but their duration was increased by the succession of multiple hypometric saccades that could clinically be confused with 'slow saccades'. We emphasize the phenotypic variability over the course of the disease. Cerebellar ataxia and/or chorea predominate at onset, but later on they are often partially masked by severe neuropathy, which is the most typical symptom in young adults. The presence of chorea, sensorimotor neuropathy, oculomotor anomalies, biological abnormalities, cerebellar atrophy on MRI and absence of the Babinski sign can help to distinguish AOA1 from Friedreich's ataxia on a clinical basis. The frequency of chorea at onset suggests that this diagnosis should also be considered in children with chorea who do not carry the IT15 mutation responsible for Huntington's disease.